Role of thrombophilic risk factors in ch (1)
Thrombosis Research (2005) 116, 133 — 137
intl.elsevierhealth.com/journals/thre
Regular Article
Role of thrombophilic risk factors in children with
non-stroke cerebral palsy
Aviva Fattal-Valevskia,b,*, Gili Kenetb,c, Michael J. Kupfermincb,d,
Ronit Mestermana,b, Yael Leitnera,b, Eli Rimonb,d, Shaul Harela,b,
Avi Hassnerb,e
a
The Institute for Child Development and Pediatric Neurology Unit, Tel Aviv Sourasky Medical Center,
Beit Habriut Strauss, 14 Balfour St., Tel Aviv 65211, Israel
b
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
c
Pediatric Coagulation Service, the National Hemophilia Center and Institute of Thrombosis and
Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel
d
The Department of Obstetrics and Gynecology, Lis Maternity Hospital,
Tel Aviv Sourasky Medical Center, Israel
e
Tel Aviv Sourasky Medical Center, Israel
Received 27 September 2004; received in revised form 16 November 2004; accepted 25 November 2004
Available online 29 December 2004
KEYWORDS
Thrombophilia;
Cerebral palsy;
MTHFR;
Factor V leiden;
Factor II
Abstract
Background: Thrombophilic risk factors play an important role in the pathogenesis of
perinatal stroke and resultant cerebral palsy (CP). The association between
thrombophilia and CP caused by etiologies other than stroke is undetermined.
Methods: We assessed three genetic thrombophilic markers (mutation of Factor V
Leiden [FV G1691A], 677T polymorphism of thermolabile methylenetetrahydrofolate
reductase [MTHFR] and G20210A mutation of the prothrombin gene) in 49 pediatric
patients with non-stroke CP and compared the findings with 118 apparently healthy
controls. CP in the study group was due to periventricular leukomalacia (n=27),
intraventricular hemorrhage (n=9), hypoxic ischemic encephalopathy (n=4), prematurity with no apparent complication (n=8) and intrauterine growth retardation
(n=1). Twenty-five children had spastic diplegia, 20 had spastic quadriplegia and 4
had spastic hemiplegia. CP was graded as being severe in 26 children (53%).
Results: No significant difference in the prevalence of thrombophilic risk factors was
found between the study and control groups. Twelve study children (24.5%) had at
least one of the three thrombophilic mutations compared with 27 controls (23%).
* Corresponding author. The Institute for Child Development and Pediatric Neurology Unit, Tel Aviv Sourasky Medical Center, Beit
Habriut Strauss, 14 Balfour St., Tel Aviv 65211, Israel. Tel.: +972 3 6423824; fax: +972 3 7441283.
E-mail address: afatal@post.tau.ac.il (A. Fattal-Valevski).
0049-3848/$ - see front matter D 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.thromres.2004.11.022
134
A. Fattal-Valevski et al.
There was no significant difference in the prevalence of each thrombophilic risk
factor in the various etiologic groups and in the subgroups of mild/severe CP and
the control group.
Conclusion: These findings support the notion that thrombophilia neither
contributes to the occurrence nor affects the clinical outcome and severity of
non-stroke CP.
D 2004 Elsevier Ltd. All rights reserved.
Introduction
Cerebral palsy (CP) is a common disorder in childhood, occurring in 2—2.5 per 1000 live births [1].
Perinatal asphyxia and prematurity play an important role in the pathogenesis of CP, but its occurrence is often triggered by other predisposing
factors, suggesting that more than a single risk
factor may be involved [2,3]. Factors such as intrauterine exposure to infection, inflammation or
coagulation disorders have been suggested as predisposing factors to brain injury [4—6]. The relation
between CP and thrombophilia has not yet been
defined [7]. It is well known that genetic prothrombotic risk factors play an important role in the
pathogenesis of infantile thrombosis [8—10], childhood stroke [11—13], perinatal stroke [14,15] and
resultant porencephaly [16] and hemiplegic CP
[17,18]. The largest known contributor reported is
Factor V Leiden mutation (FV G1691A) [15—19].
Whether or not thrombophilia plays a role in the
pathogenesis of other brain lesions that result in CP
has not been established. Some case series have
demonstrated an increased risk of intraventricular
hemorrhage (IVH), a recognized cause for CP,
in preterm infants with thrombophilia [20,21].
Another population-based study reported contrary
results, failing to demonstrate any increased risk of
IVH and periventricular leukomalacia (PVL) in premature infants with thrombophilia [22]. Therefore,
the contribution of thrombophilia to the development of non-stroke CP remains to be clarified.
Thrombophilia stems from acquired as well as
inherited causes [23]. Several mutations in coagulation proteins are associated with an increased risk
for thromboembolic complications. Resistance to
activated protein C caused by an adenine 506
guanine (A506G) mutation in FV G1691A has been
linked with an increased risk for venous thromboembolism [24] as well as childhood stroke [13].
Homozygosity for the cytosine 677 thymine (C677T)
mutation in methylenetetrahydrofolate reductase
(MTHFR) may slightly increase the risk for venous
and arterial thrombosis [25] ,and the guanine 20210
adenine mutation in prothrombin (FIIG20210A) has
been associated with increased risk for venous
thromboembolism and cerebral vein thrombosis
[26].
The present study aimed to determine the
prevalence of the abovementioned thrombophilic
risk factors in non-stroke pediatric CP patients
compared to those of a control group of apparently
normal children.
Subjects and methods
Subjects
Between September 2001 and September 2003, we
studied consecutive children with spastic CP who
were referred to a large pediatric CP referral center
in Israel. All children below 18 years of age who were
diagnosed as having CP were considered suitable
candidates for the study. Since the association of
genetic thrombophilia and childhood stroke is well
established, those children whose CP was caused by
ischemic stroke were excluded. Children with a
known familial thrombophilia, defined as either
family history positive for early (b50 years old)
thrombosis or presence of parental genetic thrombophilia, were excluded from our study as well.
Diagnosis of non-stroke CP was made by absence of a
past history of ischemic stroke and no evidence of
porencephaly on an imaging study (computerized
tomography [CT] or magnetic resonance imaging
[MRI]). Forty-nine children (mean age 4.8F2.9
years) defined as non-stroke CP who met the
inclusion criteria comprised the study group. All CP
patients were diagnosed at 6—12 months (median 8
months). The children’s ethnic origin was classified
as Ashkenazi Jewish, non-Ashkenazi Jewish, mixed
Ashkenazi and non-Ashkenazi Jewish and Arabic
(Table 1). The mean gestational age in the study
group was 31.2F4.5 weeks and the mean birth
weight was 1.65F0.87 kg.
The etiology for CP in the study group was PVL
in 27 (55%), IVH in 9 (18%) and hypoxic ischemic
encephalopathy (HIE) in 4 (8%); in eight children
(16%) the etiology was defined as prematurity
since no other cause for the development of CP
could be traced. One child had severe intrauterine
Thrombophilia and non-stroke cerebral palsy
Table 1
groups
135
Demographic data of the study and control
Number
Age (years)
Gender
Ethnicity
Ashkenazi Jews
Non-Ashkenazi Jews
Mixed Jews
Arabs
Children with non-stroke
cerebral palsy
Controls
49
4.8F2.9
M 25 (51%)
F 24 (49%)
118
8.2F3.8
69 (58%)
49 (42%)
18
15
13
3
(37%)
(31%)
(26%)
(6%)
43
42
24
7
(37%)
(36%)
(21%)
(6%)
growth retardation (IUGR). PVL was defined by one
of two criteria: periventricular cystic lesions as
seen on neonatal brain ultrasound (US) or brain MRI
showing diminished periventricular white matter,
irregular shape of the lateral ventricles or ventricular dilatation. IVH was defined according to
the grading system of Volpe [27]. Forty-two (86%)
children in our study group were preterm. In 7
children who were born at term, the etiology for
CP was HIE (n=4), IVH (n=2) and IUGR (n=1). The
study group included 25 children with spastic
diplegia, 20 with spastic quadriplegia and 4 with
spastic hemiplegia. The etiology in all children
with hemiplegic CP was IVH.
The level of severity of CP was defined according
to the functional ability and the type of CP.
Specifically, severe CP was defined as either spastic
quadriplegia and being either non-ambulatory or
mentally retarded. The remaining CP children who
were ambulatory without mental retardation were
defined as having mild CP.
The control group consisted of 118 apparently
healthy children who were recruited prior to
undergoing an elective surgical procedure or
routinely visiting ambulatory childcare clinics:
none had known familial thrombophilia defined
as either family history positive for early (b50
years old) thrombosis or presence of parental
genetic thrombophilia, history of previous thromboembolic events or neurological abnormalities.
The distribution of gender and ethnic origin was
similar in both groups (Table 1). The mean age of
the control group was 8.2F3.8 years (Table 1).
The difference in age between the two groups had
no impact upon our results since the studied
inherited mutations are genetically transmitted
and not age-dependent.
Methods
We evaluated three thrombophilic markers: mutation of Factor V Leiden, C677T polymorphism of
thermolabile MTHFR and G20210A mutation of the
prothrombin gene. Citrated blood (0.38%) was
drawn for DNA analysis of the thrombophilic
mutations from all the children at the time of
study enrollment. Molecular diagnosis of the FV
G1691A mutation was performed as described by
Dalback [28]. The mutation in the MTHFR gene
was tested by the method of Frosst et al. [25].
The mutation in the prothrombin gene was
detected by means of a slight modification of
the method of Poort et al. [26] as described by
Salomon et al. [29]. A questionnaire on birth
weight, perinatal history, family history, type and
severity of the CP, motor function, and cognitive
ability was filled out for all the children in the
study group. The information was obtained from
the medical charts and the children’s parents. The
study was approved by the Ethics Committee of
the Tel Aviv Sourasky Medical Center.
Statistical analysis
The unpaired t-test was used for between-group
comparison of birth weight and age. Prevalence of
prothrombotic risk factors in the patients and
control subjects was calculated by Fisher’s exact
test. The significance level was set at 0.05. The
odds ratios and 95% confidence intervals were
calculated in the study group compared with
controls, and in each of the three etiologic groups
of CP compared with controls. The same analysis
was performed to compare the mild with severe
CP patients.
Results
Prothrombotic risk factors in the study and
control groups
Overall, 12 of the 49 children with non-stroke CP
(24.5%) had at least one of the three thrombophilic mutations compared with 27 of the 118
normal controls (22.9%). Four study group children had FV G1691A, 9 had an MTHFR mutation
and one had FIIG20210A mutation. Two children
had combined thrombophilic mutations: one FV
G1691A and MTHFR and one FIIG20210A and
MTHFR. Both were considered only once for the
statistical analysis. No children in the control
group had combinations of thrombophilia risk
factors. There was no significant difference in
the prevalence of each thrombophilic risk factor
among the study patients and the normal controls
(Table 2).
136
A. Fattal-Valevski et al.
Table 2 Thrombophilic risk factors in the study
versus the control groups
Children with Controls
non-stroke
(n=118)
cerebral
palsy (n=49)
Thrombophilia 12a (24.5%)
FV G1691A
4 (8.2%)
MTHFR T677T
9 (18.4%)
FIIG20210A
1 (2%)
a
27
5
19
3
(22.9%)
(4.2%)
(16%)
(2.5%)
Odds 95%
ratio Confidence
Interval
1.09
2.00
1.17
0.79
0.50—2.38
0.51—7.82
0.49—2.81
0.08—7.87
Two children in the CP group had combined risk factors.
Prothrombotic risk factors in the various
etiologic groups
There was no significant difference in the prevalence of each thrombophilic risk factor in the
various etiologic groups. Seven children in the PVL
group (26%) had at least one of the three thrombophilic mutations, 2 (22%) in the IVH group, 1 (25%)
in the HIE group and 2 (25%) in the prematurity
group.
Mild vs. severe CP
Twenty-six of the CP children (53%) were defined
as having severe CP and the remaining 23 children
(47%) as having mild CP. Seven of 26 children (27%)
with severe CP were found to have at least one
prothrombotic risk factor compared with 5 children (22%) in the mild CP group. There was no
significant difference in the prevalence of each
thrombophilic risk factor among the mild and
severe CP groups (odds ratio, 1.32; 95% CI, 0.35
to 4.94). Among the children with severe CP, 3 had
FV G1691A and 4 had an MTHFR mutation. Among
the children with mild CP, 1 had FV G1691A, 5 had
an MTHFR mutation and 1 had a FIIG20210A
mutation (two had combined mutations).
FIIG20210A was similar among patients and population, in concordance with our findings [17].
These findings emphasize the importance of defining the underlying brain lesion in studies of CP
patients.
In our study the prevalence of thrombophilia
markers was similar to that of the controls in each
etiologic subgroup of CP. The majority of our CP
patients were born prematurely (n=42) and suffered from complications of prematurity, e.g. PVL
and IVH. Therefore, we conclude that thrombophilia did not contribute to the occurrence of CP in
premature infants nor in those with a history of PVL
or IVH. The fact that the majority of the study
group were premature should not affect the results
since the studied inherited mutations are genetically transmitted and do not depend on gestational
age. Moreover, previous study demonstrated that
the prevalence of thrombophilia in preterm Israeli
newborns was similar to the healthy pediatric
Israeli population [22]. However, we cannot rule
out the impact of possible undiagnosed maternal
thrombophilia upon the occurrence of prematurity
in our study population.
The prevalence of thrombophilic markers did not
differ among patients with mild or severe CP.
Therefore, the presence of thrombophilic markers
had no impact upon the neurological outcome of
our patients. On the contrary two patients with
combined thrombophilic mutation had mild CP.
In summary, the results of the current study
support the notion that thrombophilia neither
contributes to the occurrence nor affects the
clinical outcome of CP that is not attributed to
stroke, in children.
Acknowledgment
Esther Eshkol is thanked for editorial assistance.
Discussion
References
In the present case-control study, we found no
significant difference in the prevalence of FV
G1691A, FIIG20210A and MTHFR T677T between
children with non-stroke CP and normal controls.
Previous case-series that demonstrated an association between CP and thrombophilic risk factors,
mainly FV G1691A mutation, were confined to CP
that has been caused by ischemic stroke [15—18].
In another case-study of hemiplegic CP patients,
thrombophilia was increased among the subgroup
of children with radiologically confirmed ischemia, however the overall rate of FV G1691A and
[1] Mutch L, Alberman E, Hagberg B, Kodama K, Perat MV.
Cerebral palsy epidemiology: where are we now and where
are we going? Dev Med Child Neurol 1992;34:547 – 55.
[2] Nelson KB, Grether JK. Causes of cerebral palsy. Curr Opin
Pediatr 1999;11:487 – 91.
[3] Han TR, Bang MS, Lim JY, Yoon BH, Kim IW. Risk factors of
cerebral palsy in preterm infants. Am J Phys Med Rehabil
2002;81:297 – 303.
[4] Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal
cytokines and coagulation factors in children. Ann Neurol
1998;44:665 – 75.
[5] Badawi N, Kurinczuk JJ, Keogh JM, Alessandri LM, O’Sullivan
F, Burton PR, et al. Antepartum risk factors for newborn
Thrombophilia and non-stroke cerebral palsy
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
encephalopathy: the Western Australian case control study.
Br Med J 1998;317:1549 – 53.
Nelson KB. The epidemiology of cerebral palsy in term
infants. Ment Retard Dev Disabil Res Rev 2002;8:146 – 50.
Smith RA, Skelton M, Howard M, Levene M. Is thrombophilia
a factor in the development of hemiplegic cerebral palsy?
Dev Med Child Neurol 2001;43:724 – 30.
Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G,
Frontroth JP. Prethrombotic disorders in children with
ischemic stroke and sinovenous thrombosis. Arch Neurol
1999;56:967 – 71.
van Ommen CH, Heijboer H, Buller HR, Hirasing RA,
Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.
J Pediatr 2001;139:676 – 81.
Uttenreuther-Fischer MM, Vetter B, Hellmann C, Otting U,
Ziemer S, Hausdorf G, et al. Pediatric thromboembolism; the
influence of non-genetic factors and the role of activated
protein C resistance and protein C deficiency. Eur J Pediatr
1996;156:227 – 81.
De-Veber G, Andrew M, Adams C, Bjornson B, Booth F,
Buckley DJ, et al. Cerebral sinovenous thrombosis in
children. N Engl J Med 2001;345:417 – 423.
Strater R, Becker S, von Eckardstein A, Heinecke A, Gutsche
R, Junker R, et al. Prospective assessment of risk factors for
recurrent stroke during childhood—a 5-year follow-up
study. Lancet 2002;360:1540 – 5.
Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N,
Gitel S, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in
children. Stroke 2000;31:1283 – 8.
Gunther G, Junker R, Strater R, Schobess R, Kurnik K,
Heller C, et al. Childhood Stroke Study Group. Symptomatic ischemic stroke in full-term neonates: role of
acquired and genetic prothrombotic risk factors. Stroke
2000;31:2437 – 41.
Harum KH, Hoon Jr AH, Kato GJ, Casella JF, Breiter SN,
Johnston MV. Homozygous factor-V mutation as a genetic
cause of perinatal thrombosis and cerebral palsy. Dev
Med Child Neurol 1999;41:777 – 80.
Debus OM, Kosch A, Strater R, Rossi R, Nowak-Gottl U. The
factor V G1691A mutation is a risk for porencephaly: a casecontrol study. Ann Neurol 2004;56:287 – 90.
Halliday JL, Reddihough D, Byron K, Ekert H, Ditchfield M.
Hemiplegic cerebral palsy and the factor V Leiden mutation. J Med Genet 2000;37:787 – 9.
137
[18] Thorarensen O, Ryan S, Hunter J, Younkin DP. Factor V
Leiden mutation: an unrecognized cause of hemiplegic
cerebral palsy, neonatal stroke and placental thrombosis.
Ann Neurol 1997;42:372 – 5.
[19] Lynch JK, Nelson KB, Curry CJ, Grether JK. Cerebrovascular disorders in children with the factor V Leiden
mutation. J Child Neurol 2001;16:735 – 44.
[20] Petaja J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res 2001;49:643 – 6.
[21] Aronis S, Bouza H, Pergantou H, Kapsimalis Z, Platokouki H,
Xanthou M. Prothrombotic factors in neonates with cerebral
thrombosis and intraventricular hemorrhage. Acta Paediatr, Suppl 2002;91:87 – 91.
[22] Kenet G, Maayan-Metzger A, Rosenberg N, Sela B, Mazkereth
R, Ifrah A, et al. Thrombophilia does not increase risk for
neonatal complications in preterm infants. Thromb Haemost 2003;90:823 – 8.
[23] Seligsohn U, Lubetsky A. Genetic susceptibility to venous
thrombosis. N Engl J Med 2001;344:1222 – 31.
[24] Bertina RM, Koeleman RPC, Koster T. Mutation in blood
coagulation factor V associated with resistance to activated
protein C. Nature 1994;369:64 – 7.
[25] Frosst P, Bloom HJ, Milos R, Goyette P, Sheppard CA,
Matthews RG, et al. A candidate genetic risk factor for
vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nat Genet 1995;10:111 – 3.
[26] Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A genetic
variation in the 3V-untranslated region of the prothrombin
gene is associated with elevated plasma prothrombin
levels and an increase in venous thrombosis. Blood 1996;
88:3698 – 703.
[27] Volpe JJ. Neurobiology of the newborn. Philadelphia7
Saunders; 2001. p. 217 – 497.
[28] Dalback B. New molecular insights of thrombophilia:
resistance to activated protein C caused by Arg506 to
Gln. Mutation in factor V as pathogenetic risk factor for
venous thrombosis. Thromb Haemost 1995;74:139 – 48.
[29] Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R,
Rosenberg N, et al. Single and combined prothrombotic
factors in patients with idiopathic venous thromboembolism. Arterioscler Thromb Vasc Biol 1999;19:511 – 8.
intl.elsevierhealth.com/journals/thre
Regular Article
Role of thrombophilic risk factors in children with
non-stroke cerebral palsy
Aviva Fattal-Valevskia,b,*, Gili Kenetb,c, Michael J. Kupfermincb,d,
Ronit Mestermana,b, Yael Leitnera,b, Eli Rimonb,d, Shaul Harela,b,
Avi Hassnerb,e
a
The Institute for Child Development and Pediatric Neurology Unit, Tel Aviv Sourasky Medical Center,
Beit Habriut Strauss, 14 Balfour St., Tel Aviv 65211, Israel
b
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
c
Pediatric Coagulation Service, the National Hemophilia Center and Institute of Thrombosis and
Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel
d
The Department of Obstetrics and Gynecology, Lis Maternity Hospital,
Tel Aviv Sourasky Medical Center, Israel
e
Tel Aviv Sourasky Medical Center, Israel
Received 27 September 2004; received in revised form 16 November 2004; accepted 25 November 2004
Available online 29 December 2004
KEYWORDS
Thrombophilia;
Cerebral palsy;
MTHFR;
Factor V leiden;
Factor II
Abstract
Background: Thrombophilic risk factors play an important role in the pathogenesis of
perinatal stroke and resultant cerebral palsy (CP). The association between
thrombophilia and CP caused by etiologies other than stroke is undetermined.
Methods: We assessed three genetic thrombophilic markers (mutation of Factor V
Leiden [FV G1691A], 677T polymorphism of thermolabile methylenetetrahydrofolate
reductase [MTHFR] and G20210A mutation of the prothrombin gene) in 49 pediatric
patients with non-stroke CP and compared the findings with 118 apparently healthy
controls. CP in the study group was due to periventricular leukomalacia (n=27),
intraventricular hemorrhage (n=9), hypoxic ischemic encephalopathy (n=4), prematurity with no apparent complication (n=8) and intrauterine growth retardation
(n=1). Twenty-five children had spastic diplegia, 20 had spastic quadriplegia and 4
had spastic hemiplegia. CP was graded as being severe in 26 children (53%).
Results: No significant difference in the prevalence of thrombophilic risk factors was
found between the study and control groups. Twelve study children (24.5%) had at
least one of the three thrombophilic mutations compared with 27 controls (23%).
* Corresponding author. The Institute for Child Development and Pediatric Neurology Unit, Tel Aviv Sourasky Medical Center, Beit
Habriut Strauss, 14 Balfour St., Tel Aviv 65211, Israel. Tel.: +972 3 6423824; fax: +972 3 7441283.
E-mail address: afatal@post.tau.ac.il (A. Fattal-Valevski).
0049-3848/$ - see front matter D 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.thromres.2004.11.022
134
A. Fattal-Valevski et al.
There was no significant difference in the prevalence of each thrombophilic risk
factor in the various etiologic groups and in the subgroups of mild/severe CP and
the control group.
Conclusion: These findings support the notion that thrombophilia neither
contributes to the occurrence nor affects the clinical outcome and severity of
non-stroke CP.
D 2004 Elsevier Ltd. All rights reserved.
Introduction
Cerebral palsy (CP) is a common disorder in childhood, occurring in 2—2.5 per 1000 live births [1].
Perinatal asphyxia and prematurity play an important role in the pathogenesis of CP, but its occurrence is often triggered by other predisposing
factors, suggesting that more than a single risk
factor may be involved [2,3]. Factors such as intrauterine exposure to infection, inflammation or
coagulation disorders have been suggested as predisposing factors to brain injury [4—6]. The relation
between CP and thrombophilia has not yet been
defined [7]. It is well known that genetic prothrombotic risk factors play an important role in the
pathogenesis of infantile thrombosis [8—10], childhood stroke [11—13], perinatal stroke [14,15] and
resultant porencephaly [16] and hemiplegic CP
[17,18]. The largest known contributor reported is
Factor V Leiden mutation (FV G1691A) [15—19].
Whether or not thrombophilia plays a role in the
pathogenesis of other brain lesions that result in CP
has not been established. Some case series have
demonstrated an increased risk of intraventricular
hemorrhage (IVH), a recognized cause for CP,
in preterm infants with thrombophilia [20,21].
Another population-based study reported contrary
results, failing to demonstrate any increased risk of
IVH and periventricular leukomalacia (PVL) in premature infants with thrombophilia [22]. Therefore,
the contribution of thrombophilia to the development of non-stroke CP remains to be clarified.
Thrombophilia stems from acquired as well as
inherited causes [23]. Several mutations in coagulation proteins are associated with an increased risk
for thromboembolic complications. Resistance to
activated protein C caused by an adenine 506
guanine (A506G) mutation in FV G1691A has been
linked with an increased risk for venous thromboembolism [24] as well as childhood stroke [13].
Homozygosity for the cytosine 677 thymine (C677T)
mutation in methylenetetrahydrofolate reductase
(MTHFR) may slightly increase the risk for venous
and arterial thrombosis [25] ,and the guanine 20210
adenine mutation in prothrombin (FIIG20210A) has
been associated with increased risk for venous
thromboembolism and cerebral vein thrombosis
[26].
The present study aimed to determine the
prevalence of the abovementioned thrombophilic
risk factors in non-stroke pediatric CP patients
compared to those of a control group of apparently
normal children.
Subjects and methods
Subjects
Between September 2001 and September 2003, we
studied consecutive children with spastic CP who
were referred to a large pediatric CP referral center
in Israel. All children below 18 years of age who were
diagnosed as having CP were considered suitable
candidates for the study. Since the association of
genetic thrombophilia and childhood stroke is well
established, those children whose CP was caused by
ischemic stroke were excluded. Children with a
known familial thrombophilia, defined as either
family history positive for early (b50 years old)
thrombosis or presence of parental genetic thrombophilia, were excluded from our study as well.
Diagnosis of non-stroke CP was made by absence of a
past history of ischemic stroke and no evidence of
porencephaly on an imaging study (computerized
tomography [CT] or magnetic resonance imaging
[MRI]). Forty-nine children (mean age 4.8F2.9
years) defined as non-stroke CP who met the
inclusion criteria comprised the study group. All CP
patients were diagnosed at 6—12 months (median 8
months). The children’s ethnic origin was classified
as Ashkenazi Jewish, non-Ashkenazi Jewish, mixed
Ashkenazi and non-Ashkenazi Jewish and Arabic
(Table 1). The mean gestational age in the study
group was 31.2F4.5 weeks and the mean birth
weight was 1.65F0.87 kg.
The etiology for CP in the study group was PVL
in 27 (55%), IVH in 9 (18%) and hypoxic ischemic
encephalopathy (HIE) in 4 (8%); in eight children
(16%) the etiology was defined as prematurity
since no other cause for the development of CP
could be traced. One child had severe intrauterine
Thrombophilia and non-stroke cerebral palsy
Table 1
groups
135
Demographic data of the study and control
Number
Age (years)
Gender
Ethnicity
Ashkenazi Jews
Non-Ashkenazi Jews
Mixed Jews
Arabs
Children with non-stroke
cerebral palsy
Controls
49
4.8F2.9
M 25 (51%)
F 24 (49%)
118
8.2F3.8
69 (58%)
49 (42%)
18
15
13
3
(37%)
(31%)
(26%)
(6%)
43
42
24
7
(37%)
(36%)
(21%)
(6%)
growth retardation (IUGR). PVL was defined by one
of two criteria: periventricular cystic lesions as
seen on neonatal brain ultrasound (US) or brain MRI
showing diminished periventricular white matter,
irregular shape of the lateral ventricles or ventricular dilatation. IVH was defined according to
the grading system of Volpe [27]. Forty-two (86%)
children in our study group were preterm. In 7
children who were born at term, the etiology for
CP was HIE (n=4), IVH (n=2) and IUGR (n=1). The
study group included 25 children with spastic
diplegia, 20 with spastic quadriplegia and 4 with
spastic hemiplegia. The etiology in all children
with hemiplegic CP was IVH.
The level of severity of CP was defined according
to the functional ability and the type of CP.
Specifically, severe CP was defined as either spastic
quadriplegia and being either non-ambulatory or
mentally retarded. The remaining CP children who
were ambulatory without mental retardation were
defined as having mild CP.
The control group consisted of 118 apparently
healthy children who were recruited prior to
undergoing an elective surgical procedure or
routinely visiting ambulatory childcare clinics:
none had known familial thrombophilia defined
as either family history positive for early (b50
years old) thrombosis or presence of parental
genetic thrombophilia, history of previous thromboembolic events or neurological abnormalities.
The distribution of gender and ethnic origin was
similar in both groups (Table 1). The mean age of
the control group was 8.2F3.8 years (Table 1).
The difference in age between the two groups had
no impact upon our results since the studied
inherited mutations are genetically transmitted
and not age-dependent.
Methods
We evaluated three thrombophilic markers: mutation of Factor V Leiden, C677T polymorphism of
thermolabile MTHFR and G20210A mutation of the
prothrombin gene. Citrated blood (0.38%) was
drawn for DNA analysis of the thrombophilic
mutations from all the children at the time of
study enrollment. Molecular diagnosis of the FV
G1691A mutation was performed as described by
Dalback [28]. The mutation in the MTHFR gene
was tested by the method of Frosst et al. [25].
The mutation in the prothrombin gene was
detected by means of a slight modification of
the method of Poort et al. [26] as described by
Salomon et al. [29]. A questionnaire on birth
weight, perinatal history, family history, type and
severity of the CP, motor function, and cognitive
ability was filled out for all the children in the
study group. The information was obtained from
the medical charts and the children’s parents. The
study was approved by the Ethics Committee of
the Tel Aviv Sourasky Medical Center.
Statistical analysis
The unpaired t-test was used for between-group
comparison of birth weight and age. Prevalence of
prothrombotic risk factors in the patients and
control subjects was calculated by Fisher’s exact
test. The significance level was set at 0.05. The
odds ratios and 95% confidence intervals were
calculated in the study group compared with
controls, and in each of the three etiologic groups
of CP compared with controls. The same analysis
was performed to compare the mild with severe
CP patients.
Results
Prothrombotic risk factors in the study and
control groups
Overall, 12 of the 49 children with non-stroke CP
(24.5%) had at least one of the three thrombophilic mutations compared with 27 of the 118
normal controls (22.9%). Four study group children had FV G1691A, 9 had an MTHFR mutation
and one had FIIG20210A mutation. Two children
had combined thrombophilic mutations: one FV
G1691A and MTHFR and one FIIG20210A and
MTHFR. Both were considered only once for the
statistical analysis. No children in the control
group had combinations of thrombophilia risk
factors. There was no significant difference in
the prevalence of each thrombophilic risk factor
among the study patients and the normal controls
(Table 2).
136
A. Fattal-Valevski et al.
Table 2 Thrombophilic risk factors in the study
versus the control groups
Children with Controls
non-stroke
(n=118)
cerebral
palsy (n=49)
Thrombophilia 12a (24.5%)
FV G1691A
4 (8.2%)
MTHFR T677T
9 (18.4%)
FIIG20210A
1 (2%)
a
27
5
19
3
(22.9%)
(4.2%)
(16%)
(2.5%)
Odds 95%
ratio Confidence
Interval
1.09
2.00
1.17
0.79
0.50—2.38
0.51—7.82
0.49—2.81
0.08—7.87
Two children in the CP group had combined risk factors.
Prothrombotic risk factors in the various
etiologic groups
There was no significant difference in the prevalence of each thrombophilic risk factor in the
various etiologic groups. Seven children in the PVL
group (26%) had at least one of the three thrombophilic mutations, 2 (22%) in the IVH group, 1 (25%)
in the HIE group and 2 (25%) in the prematurity
group.
Mild vs. severe CP
Twenty-six of the CP children (53%) were defined
as having severe CP and the remaining 23 children
(47%) as having mild CP. Seven of 26 children (27%)
with severe CP were found to have at least one
prothrombotic risk factor compared with 5 children (22%) in the mild CP group. There was no
significant difference in the prevalence of each
thrombophilic risk factor among the mild and
severe CP groups (odds ratio, 1.32; 95% CI, 0.35
to 4.94). Among the children with severe CP, 3 had
FV G1691A and 4 had an MTHFR mutation. Among
the children with mild CP, 1 had FV G1691A, 5 had
an MTHFR mutation and 1 had a FIIG20210A
mutation (two had combined mutations).
FIIG20210A was similar among patients and population, in concordance with our findings [17].
These findings emphasize the importance of defining the underlying brain lesion in studies of CP
patients.
In our study the prevalence of thrombophilia
markers was similar to that of the controls in each
etiologic subgroup of CP. The majority of our CP
patients were born prematurely (n=42) and suffered from complications of prematurity, e.g. PVL
and IVH. Therefore, we conclude that thrombophilia did not contribute to the occurrence of CP in
premature infants nor in those with a history of PVL
or IVH. The fact that the majority of the study
group were premature should not affect the results
since the studied inherited mutations are genetically transmitted and do not depend on gestational
age. Moreover, previous study demonstrated that
the prevalence of thrombophilia in preterm Israeli
newborns was similar to the healthy pediatric
Israeli population [22]. However, we cannot rule
out the impact of possible undiagnosed maternal
thrombophilia upon the occurrence of prematurity
in our study population.
The prevalence of thrombophilic markers did not
differ among patients with mild or severe CP.
Therefore, the presence of thrombophilic markers
had no impact upon the neurological outcome of
our patients. On the contrary two patients with
combined thrombophilic mutation had mild CP.
In summary, the results of the current study
support the notion that thrombophilia neither
contributes to the occurrence nor affects the
clinical outcome of CP that is not attributed to
stroke, in children.
Acknowledgment
Esther Eshkol is thanked for editorial assistance.
Discussion
References
In the present case-control study, we found no
significant difference in the prevalence of FV
G1691A, FIIG20210A and MTHFR T677T between
children with non-stroke CP and normal controls.
Previous case-series that demonstrated an association between CP and thrombophilic risk factors,
mainly FV G1691A mutation, were confined to CP
that has been caused by ischemic stroke [15—18].
In another case-study of hemiplegic CP patients,
thrombophilia was increased among the subgroup
of children with radiologically confirmed ischemia, however the overall rate of FV G1691A and
[1] Mutch L, Alberman E, Hagberg B, Kodama K, Perat MV.
Cerebral palsy epidemiology: where are we now and where
are we going? Dev Med Child Neurol 1992;34:547 – 55.
[2] Nelson KB, Grether JK. Causes of cerebral palsy. Curr Opin
Pediatr 1999;11:487 – 91.
[3] Han TR, Bang MS, Lim JY, Yoon BH, Kim IW. Risk factors of
cerebral palsy in preterm infants. Am J Phys Med Rehabil
2002;81:297 – 303.
[4] Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal
cytokines and coagulation factors in children. Ann Neurol
1998;44:665 – 75.
[5] Badawi N, Kurinczuk JJ, Keogh JM, Alessandri LM, O’Sullivan
F, Burton PR, et al. Antepartum risk factors for newborn
Thrombophilia and non-stroke cerebral palsy
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
encephalopathy: the Western Australian case control study.
Br Med J 1998;317:1549 – 53.
Nelson KB. The epidemiology of cerebral palsy in term
infants. Ment Retard Dev Disabil Res Rev 2002;8:146 – 50.
Smith RA, Skelton M, Howard M, Levene M. Is thrombophilia
a factor in the development of hemiplegic cerebral palsy?
Dev Med Child Neurol 2001;43:724 – 30.
Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G,
Frontroth JP. Prethrombotic disorders in children with
ischemic stroke and sinovenous thrombosis. Arch Neurol
1999;56:967 – 71.
van Ommen CH, Heijboer H, Buller HR, Hirasing RA,
Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.
J Pediatr 2001;139:676 – 81.
Uttenreuther-Fischer MM, Vetter B, Hellmann C, Otting U,
Ziemer S, Hausdorf G, et al. Pediatric thromboembolism; the
influence of non-genetic factors and the role of activated
protein C resistance and protein C deficiency. Eur J Pediatr
1996;156:227 – 81.
De-Veber G, Andrew M, Adams C, Bjornson B, Booth F,
Buckley DJ, et al. Cerebral sinovenous thrombosis in
children. N Engl J Med 2001;345:417 – 423.
Strater R, Becker S, von Eckardstein A, Heinecke A, Gutsche
R, Junker R, et al. Prospective assessment of risk factors for
recurrent stroke during childhood—a 5-year follow-up
study. Lancet 2002;360:1540 – 5.
Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N,
Gitel S, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in
children. Stroke 2000;31:1283 – 8.
Gunther G, Junker R, Strater R, Schobess R, Kurnik K,
Heller C, et al. Childhood Stroke Study Group. Symptomatic ischemic stroke in full-term neonates: role of
acquired and genetic prothrombotic risk factors. Stroke
2000;31:2437 – 41.
Harum KH, Hoon Jr AH, Kato GJ, Casella JF, Breiter SN,
Johnston MV. Homozygous factor-V mutation as a genetic
cause of perinatal thrombosis and cerebral palsy. Dev
Med Child Neurol 1999;41:777 – 80.
Debus OM, Kosch A, Strater R, Rossi R, Nowak-Gottl U. The
factor V G1691A mutation is a risk for porencephaly: a casecontrol study. Ann Neurol 2004;56:287 – 90.
Halliday JL, Reddihough D, Byron K, Ekert H, Ditchfield M.
Hemiplegic cerebral palsy and the factor V Leiden mutation. J Med Genet 2000;37:787 – 9.
137
[18] Thorarensen O, Ryan S, Hunter J, Younkin DP. Factor V
Leiden mutation: an unrecognized cause of hemiplegic
cerebral palsy, neonatal stroke and placental thrombosis.
Ann Neurol 1997;42:372 – 5.
[19] Lynch JK, Nelson KB, Curry CJ, Grether JK. Cerebrovascular disorders in children with the factor V Leiden
mutation. J Child Neurol 2001;16:735 – 44.
[20] Petaja J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res 2001;49:643 – 6.
[21] Aronis S, Bouza H, Pergantou H, Kapsimalis Z, Platokouki H,
Xanthou M. Prothrombotic factors in neonates with cerebral
thrombosis and intraventricular hemorrhage. Acta Paediatr, Suppl 2002;91:87 – 91.
[22] Kenet G, Maayan-Metzger A, Rosenberg N, Sela B, Mazkereth
R, Ifrah A, et al. Thrombophilia does not increase risk for
neonatal complications in preterm infants. Thromb Haemost 2003;90:823 – 8.
[23] Seligsohn U, Lubetsky A. Genetic susceptibility to venous
thrombosis. N Engl J Med 2001;344:1222 – 31.
[24] Bertina RM, Koeleman RPC, Koster T. Mutation in blood
coagulation factor V associated with resistance to activated
protein C. Nature 1994;369:64 – 7.
[25] Frosst P, Bloom HJ, Milos R, Goyette P, Sheppard CA,
Matthews RG, et al. A candidate genetic risk factor for
vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nat Genet 1995;10:111 – 3.
[26] Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A genetic
variation in the 3V-untranslated region of the prothrombin
gene is associated with elevated plasma prothrombin
levels and an increase in venous thrombosis. Blood 1996;
88:3698 – 703.
[27] Volpe JJ. Neurobiology of the newborn. Philadelphia7
Saunders; 2001. p. 217 – 497.
[28] Dalback B. New molecular insights of thrombophilia:
resistance to activated protein C caused by Arg506 to
Gln. Mutation in factor V as pathogenetic risk factor for
venous thrombosis. Thromb Haemost 1995;74:139 – 48.
[29] Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R,
Rosenberg N, et al. Single and combined prothrombotic
factors in patients with idiopathic venous thromboembolism. Arterioscler Thromb Vasc Biol 1999;19:511 – 8.